Portalac syrup 667mg / ml 500ml
Dosage:
667mg / ml x 250ml
667mg / ml x 500ml
Category
Laxatives
Scope of the drug
Gastrointestinal tract
Release form
Syrup
Manufacturer country
Croatia
Package quantity, pcs
one
Release form, composition and packaging The syrup is transparent, viscous, from colorless to brownish-yellow.
1 ml
lactulose
667 mg
purified water.
250 ml - polyethylene bottles (1) - cardboard packs. 500 ml - polyethylene bottles (1) - cardboard packs. Pharmacological action Laxative. It causes a change in the flora of the colon (an increase in the number of lactobacilli), which leads to an increase in acidity in the lumen of the colon and stimulates its peristalsis. Along with this, the volume increases and the feces soften. As a result, a laxative effect develops, without a direct effect on the mucous membrane and smooth muscles of the colon. Under the action of lactulose, there is also the absorption of ammonia in the colon, a decrease in the formation of nitrogen-containing toxic substances in its proximal section and, accordingly, their absorption into the vena cava system. Has the ability to inhibit the growth of Salmonella in the colon.Does not decrease absorption of vitamins and is not addictive. Virtually not absorbed from the intestine. Pharmacokinetics After ingestion, lactulose by passage passes into the colon, where it is metabolized by bacteria that break down sugar. As a result, simple organic acids are formed - mainly lactic acid and to a lesser extent acetic and formic acid. A small amount of lactulose is absorbed and excreted in the urine unchanged. Indications for use Constipation, incl. chronic, during pregnancy, hemorrhoids after surgery on the colon and / or in the anal area, to prepare for surgery on the colon for softening the stool (facilitating bowel movements) with pain syndrome after removal of hemorrhoids hepatic encephalopathy hepatic precoma and coma.Contraindications to use Rectal bleeding colo-, ileostomy suspicion of appendicitis galactosemia patients with lactose intolerance, lactase deficiency, glucose-galactose malabsorption intestinal obstruction hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses exceeding the recommended ones, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses higher than recommended, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses higher than recommended, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.
When used in high doses for a long time for the prevention and treatment of hepatic precoma and coma, diarrhea and impaired water-electrolyte metabolism are possible.
From the nervous system: rarely - convulsions, headache, dizziness.
Others: possibly - allergic reactions
rarely - arrhythmias, myalgia, increased fatigue, weakness. Drug interaction With simultaneous use with broad-spectrum antibiotics, the therapeutic efficacy of lactulose may decrease.
With the simultaneous use of lactulose can disrupt the release of active substances from enteric drugs with pH-dependent release due to the fact that it lowers the pH of the intestinal contents. Application during pregnancy and lactation. should be used for abdominal pain, nausea, vomiting without verification of the diagnosis.
Use with caution in patients with gastrocardial syndrome.
In such cases, treatment should be started with low doses and increased gradually to avoid the development of flatulence.
Use with caution in patients with diabetes mellitus, especially with inflammatory lesions of the colon.
With long-term treatment (more than 6 months), the level of potassium, chlorine and carbon dioxide in the blood plasma should be regularly monitored.
If diarrhea occurs, lactulose should be discontinued.
Name ENG
PORTALAK
Clinical and pharmacological group
A laxative drug with osmotic properties.
Hypoammonic remedy
ATX code
Lactulose
Dosage
667mg / ml x 500ml
Structure
100 ml of syrup contains: active ingredient: lactulose concentrate - 96 ml (containing: lactulose - 69.4 g, water - 65.6 ml)
auxiliary substances: water -4 ml.
INN / Active ingredient
lactulose
Storage conditions and periods
At a temperature not exceeding 25 degrees (do not freeze).
Expiration date: 3 years
Specifications
Category
Laxatives
Scope of the drug
Gastrointestinal tract
Release form
Syrup
Manufacturer country
Croatia
Package quantity, pcs
one
Scope of application
Gastroenterology
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Belupo
The amount of the dosage form in the primary package
500 ml
Primary packaging type
Polyethylene bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Laxative
Anatomical and therapeutic characteristics
A06AD11 Lactulose
Dosage form
Syrup
Expiration date in days
1095
Dosage (volume) of the substance in the preparation
667 mg
Package weight, g
760